Effects of Add-on Ramelteon on Cognitive Impairment in Patients with Schizophrenia: An Open-label Pilot Trial
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: This open-label study examined the effects of ramelteon on cognitive functions in 10 outpatients with schizophrenia. Methods: Ramelteon (8 mg/day) was administered to 10 patients with schizophrenia for six months. The verbal fluency test,Trail-Making Test, the Wisconsin Card Sorting Test, the Stroop Test, the Digit Span Distraction Test, Iowa Gambling Task, theRey Auditory Verbal Learning Test were evaluated at baseline and 6 months after treatment with ramelteon. Results: Ramelteon improved significantly the scores of Rey Auditory Verbal Learning Test. Additionally, ramelteon exerted improvementsin the verbal fluency and Iowa Gambling Task in 4 patients. Conclusion: Ramelteon could be a potential therapeutic drug, in adjunctive treatment of learning and memory deficits seenin patients with schizophrenia.
Abstract
Objective: This open-label study examined the effects of ramelteon on cognitive functions in 10 outpatients with schizophrenia. Methods: Ramelteon (8 mg/day) was administered to 10 patients with schizophrenia for six months. The verbal fluency test,Trail-Making Test, the Wisconsin Card Sorting Test, the Stroop Test, the Digit Span Distraction Test, Iowa Gambling Task, theRey Auditory Verbal Learning Test were evaluated at baseline and 6 months after treatment with ramelteon. Results: Ramelteon improved significantly the scores of Rey Auditory Verbal Learning Test. Additionally, ramelteon exerted improvementsin the verbal fluency and Iowa Gambling Task in 4 patients. Conclusion: Ramelteon could be a potential therapeutic drug, in adjunctive treatment of learning and memory deficits seenin patients with schizophrenia.
참고문헌 (20)
- Sponheim SR, "Cognitive deficits in recent-onset and chronic schizophrenia", J Psychiatr Res, 44, pp.421~428 (2010)
- Ammari N, "An investigation of 3 neurocognitive subtypes in schizophrenia", Schizophr Res, 121, pp.32~38 (2010)
- Elvevåg B, "Cognitive impairment in schizophrenia is the core of the disorder", Crit Rev Neurobiol, 14, pp.1~21 (2000)
- Green MF., "Stimulating the development of drug treatments to improve cognition in schizophrenia", Annu Rev Clin Psychol, 3, pp.159~180 (2007)
- Shirayama Y, "Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: a preliminary study", Neuroimage, 49, pp.2783~2790 (2010)
- Harvey PD, "Pharmacological approaches to the management of cognitive dysfunction in schizophrenia", Drugs, 66, pp.1465~1473 (2006)
- Kern RS, "The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine", Psychopharmacology (Berl), 187, pp.312~320 (2006)
- Norris ER, "A double-blind, randomized, placebocontrolled trial of adjunctive ramelteon for the treatment of insomnia and mood stability in patients with euthymic bipolar disorder", J Affect Disord, 144, pp.141~147 (2013)
- McElroy SL, "A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance", Int Clin Psychopharmacol, 26, pp.48~53 (2011)
- Hatta K, "DELIRIA-J Group. Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial", JAMA Psychiatry, 71, pp.397~403 (2014)
- Borba CP, "Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia", J Clin Psychopharmacol, 31, pp.653~658 (2011)
- Zhang L, "Melatonin ameliorates cognitive impairment induced by sleep deprivation in rats: role of oxidative stress, BDNF and CaMKII", Behav Brain Res, 256, pp.72~81 (2013)
- Lehtinen EK, "Effects of melatonin on prepulse inhibition, habituation and sensitization of the human startle reflex in healthy volunteers", Psychiatry Res, 216, pp.418~423 (2014)
- Woods SW., "Chlorpromazine equivalent doses for the newer atypical antipsychotics", J Clin Psychiatry, 64, pp.663~667 (2003)
- Anthony A. Grace, "Hippocampal Dysregulation of Dopamine System Activity as a Pathophysiological Basis for Psychosis in Schizophrenia", Clinical Psychopharmacology and Neuroscience, 8(1), pp.1~9 (2010), 대한정신약물학회
- Fanget F, "Nocturnal plasma melatonin levels in schizophrenic patients", Biol Psychiatry, 25, pp.499~501 (1989)
- Monteleone P, "Decreased nocturnal secretion of melatonin in drug-free schizophrenics:no change after subchronic treatment with antipsychotics", Neuropsychobiology, 36, pp.159~163 (1997)
- Hagiwara H, "Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors", Eur Neuropsychopharmacol, 18, pp.448~454 (2008)
- Bertaina-Anglade V, "Memory facilitating effects of agomelatine in the novel object recognition memory paradigm in the rat", Pharmacol Biochem Behav, 98, pp.511~517 (2011)
- Larson J, "Impaired hippocampal long-term potentiation in melatonin MT2 receptor-deficient mice", Neurosci Lett, 393, pp.23~26 (2006)